OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Cancer is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Editorial Board	413
Standardization of viability assays and high-content live-cell imaging protocols for large-scale drug testing in prostate cancer PDX-derived organoids	264
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies	196
Gene expression-based prediction of pazopanib efficacy in sarcoma	175
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma	172
Corrigendum to ‘Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Jour	151
Editorial Board	147
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizum	146
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	145
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis	134
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)	132
Early versus late response to PD-1-based immunotherapy in metastatic melanoma	130
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01	123
Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck	110
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System	109
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	101
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	100
Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	100
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma	99
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy	98
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study	94
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents	93
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need	89
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study	87
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment	84

A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy	84
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases	82
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas	82
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica	81
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1	80
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins	78
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story	77
250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia	74
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC	73
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	73
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types	70
417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	67
300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers	67
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue	67
441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity	66
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development	65
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer	65
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis	64
Unexpectedly high seroprevalance of Kaposi's sarcoma-associated herpesvirus (HHV-8) in patients with stage IV melanoma	62
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	60
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	59
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	59
The role of a patient with breast cancer in a multidisciplinary team – from making a decision to changing the treatment option	59
Macular type of primary cutaneous B-cell lymphoma: extension of the clinical and histopathological patterns	59
Spectrum of dermo-epidermic cutaneous gamma-delta lymphomas from a single center: clinical and phenotypic analysis of an heterogenous lymphoproliferative disorder	59
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	59
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	58
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	57
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	57
Discovery of Essential microRNA in Prostate Cancer Cells	57
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	56
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	56
Non-clinical identification and characterization of KRAS G12D inhibitors	56